Biotechnology Industry Soars in 2012 as FDA Drug Approvals at a 15-Year High
News | 01 February 2013
NEW YORK, NY--(Marketwire - Feb 1, 2013) - A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ Biotechnology Index (IBB), the SPDR S&P Biotech ...
Click on the link to read the full article at Marketwire (press release)
(This link will open in a new window)
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
